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–0.084 to 0.194) and mortality (ARR 0.058, 95% CI –0.017 to 
0.134). Spearman correlation showed an inverse association 
between methodological quality and ARR for mortality 
(correlation coefficient –0.841, p = 0.036).  Conclusions: The 
inverse relationship between methodological quality and 
impact of antibiotic prophylaxis on mortality emphasizes 
the importance of high-quality RCTs. At present, adequate 
evidence for the routine use of antibiotic prophylaxis in se-
vere acute pancreatitis is lacking. 
 Copyright © 2007 S. Karger AG, Basel and IAP 
 Introduction 
 Acute pancreatitis has an uncomplicated course in the 
majority of patients. However, approximately one fifth of 
patients will develop severe acute pancreatitis  [1] . The 
majority of patients with severe acute pancreatitis suffer 
from complications, with an overall mortality of up to 
30%  [2] . Mortality is largely related to multi-organ failure 
early after the onset of pancreatitis and secondary infec-
tion of pancreatic necrosis by enteric bacteria during a 
second hit of the systemic inflammatory response syn-
drome  [1, 2] . Systemic antibiotic prophylaxis has been 
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 Abstract 
 Aim: To evaluate the methodological quality of randomized 
controlled trials (RCTs) of systemic antibiotic prophylaxis
in severe acute pancreatitis in relation to outcome.  Meth-
ods: The MEDLINE, EMBASE and Cochrane databases were 
searched for RCTs that studied the effectiveness of systemic 
antibiotic prophylaxis in severe acute pancreatitis. A meta-
analysis was performed with a random effects model. Meth-
odological quality was quantified by a previously published 
scoring system (range 0–17 points).  Results: Six studies, with 
a total of 397 participants, obtained a methodological score 
of at least 5 points and were included. Systemic antibiotic 
prophylaxis had no significant effect on infection of pancre-
atic necrosis (absolute risk reduction (ARR) 0.055; 95% CI
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suggested as a strategy to prevent infection of pancreatic 
necrosis and consequently reduce mortality. Several ran-
domized controlled trials (RCTs) have been performed to 
evaluate the efficacy of this strategy.
 Although the results of these trials are conflicting, 
various guidelines  [3, 4] and meta-analyses  [5, 6] advo-
cate the use of antibiotic prophylaxis in severe acute 
pancreatitis. However, these recommendations were 
published before the results of the first placebo-con-
trolled RCT became available, which failed to demon-
strate a beneficial effect of systemic antibiotic prophy-
laxis  [7] . Nevertheless, two recent meta-analyses both 
including this trial still came to conflicting results  [8, 9] . 
At present, there is no international consensus on the 
use of antibiotic prophylaxis in severe acute pancreati-
tis.
 One of the main reasons for the lack of consensus is 
the frequently criticized methodological quality of the 
published RCTs  [10] . The quality of these trials has never 
been systematically assessed. Recently, a scoring system 
was published that provides a quantitative measure of the 
methodological quality of RCTs  [11] . We aimed to evalu-
ate the evidence for routine administration of systemic 
antibiotic prophylaxis in patients with severe acute pan-
creatitis through both assessment of the methodological 
quality of the published RCTs and subsequent meta-anal-
ysis.
 Methods 
 The MEDLINE, EMBASE and Cochrane databases were 
searched for studies on intravenous antibiotic prophylaxis pub-
lished since 1990 using the search strategy shown in  figure 1 . 
Studies which compared the effectiveness of different antibiotic 
regimes or the effectiveness of different administration routes 
were excluded. There were no language restrictions, non-English 
manuscripts were translated.
 Studies on selective decontamination of the digestive tract 
(SDD) were not included in the present analysis as they focus on 
a different prophylactic mechanism. SDD aims at preventing bac-
terial translocation from the gut prior to infection, whereas sys-
temic antibiotic prophylaxis aims to diminish potential hematog-
enous spread of bacteria after translocation has occurred and/or 
to treat infection of (peri-)pancreatic necrosis.
 The methodological quality of the retrieved RCTs was as-
sessed using the previously published scoring system, which was 
adapted to the situation in severe acute pancreatitis in accordance 
with the revised CONSORT statement  [12] . The following items 
were added to the scoring system: antibiotic intervention, method 
of feeding and participant flow. Three main items (population, 
intervention and participant flow), subdivided into eight criteria 
were scored. Zero, one or two points were given for each of the 
eight criteria ( table 1 ).
 Since the participant flow item is not subdivided into further 
criteria, a third point could be obtained for participant flow in 
order to weigh the items more equally in the final score. As a re-
sult, the maximum score for study quality was 17 points ( table 1 ). 
Three researchers independently reviewed all studies (A.C.d.V., 
M.G.H.B., C.I.B.v.d.K.). In case of discrepant judgments a consen-
sus reading followed. In order to include only studies of sufficient 
methodological quality in further analysis, in accordance with 
the study by van Nieuwenhoven et al.  [11] , a cutoff methodologi-
cal score of 5 points was used.
 Subsequently, meta-analysis of the trials was performed with 
a random effects model, thereby modeling the inter-study vari-
ance to estimate the overall effect of systemic antibiotic prophy-
laxis in severe acute pancreatitis.
 The relation between the methodological quality of the studies 
and reported outcomes on infection of pancreatic necrosis and 
mortality was evaluated with a Spearman correlation coefficient, 
accounting for within-study variances. Significance was taken at 
p  ! 0.05.
Medline:
Exclusion based on:
- Antibiotic prophylaxis not main subject: 49
- Not a randomized controlled trial: 25
- Randomized controlled trial with other
study objective: 4
Pancreatitis AND antibiotic AND randomized
Limits: from 1990
84 articles




- Antibiotic prophylaxis not main subject: 140
- Not a randomized controlled trial: 25
- Randomized controlled trial with other
study objective: 2
Pancreatitis AND antibiotics
Publications from 1990, human, article
172 articles
5 articles (Spicak, Spicak, Schwarz, Delcenserie,
Pederzoli)
 Fig. 1. Search strategy. 
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 Results 
 From 256 articles screened ( fig. 1 ), 8 RCTs fulfilled the 
inclusion criteria  [7, 13–19] . Two Czech trials were trans-
lated into English  [17, 18] . The study of Nordback et al. 
 [20] was excluded as antibiotic prophylaxis was used in 
both arms of the study.
 Methodological Quality 
 The methodological quality score varied from 2 points 
for Spicak et al.  [17] to 15 points for Isenmann et al.  [7] 
and Dellinger et al.  [19] ( table 2 ). Both Czech trials  [17, 18] 
scored less than 5 points and were consequently excluded 
( table 3 ).
 Patient Characteristics 
 According to the methodological quality assessment, 
only Isenmann et al.  [7] randomized patients into highly 
comparable groups. In most studies various baseline 
characteristics were not reported. Pederzoli et al.  [14] in-
cluded significantly more patients with more than 50% 
pancreatic necrosis in the antibiotic group.
 Blinding 
 The studies of Isenmann et al.  [7] and Dellinger et al. 
 [19] were the only ones with a double-blind placebo-con-
trolled design. Delcenserie et al.  [13] and Schwarz et al. 
 [16] did not clearly define the difference between ‘antibi-
otic prophylaxis’ and ‘antibiotics on demand’, possibly 
introducing bias.
 Method of Feeding 
 The association of enteral feeding with a significantly 
lower incidence of infections has clearly been demon-
strated  [21] . Three studies  [7, 15, 16] , including the pla-
cebo-controlled trial from Isenmann et al.  [7] , did not 
state the method of feeding.
 Participant Flow 
 Isenmann et al.  [7] and Dellinger et al.  [19] described 
the participant flow explicitly; the other trials did not 
mention the loss to follow-up and whether an intention-
to-treat analysis was performed.
 Meta-Analysis 
 The 6 RCTs with a methodological quality score of at 
least 5 points were included in the meta-analysis  [7, 13–
16, 19] . In total, 203 patients received antibiotic prophy-
laxis; 194 patients were included in the control group. For 
the individual studies the absolute risk reduction (ARR) 




2 Consecutive eligible consenting patients or random series
1 Attempt made to enroll as such, with failure due to
reasons explicitly outlined
0 Selected patients (not consecutive or random) or not
described
Patient characteristics
2 Groups comparable on ≥7 characteristics
1 Groups comparable on 4–6 characteristics
0 Groups comparable on ≤3 characteristics
Age (mean differs by <10%)
Sex (proportion of men in each group differs by <10%)
Ranson score (median differs by <1 point)
Mean maximum C-reactive protein in first 48 h
(mean differs by <10%)
Pancreatic necrosis presence (proportion of patients
differs by <10%)
>30% pancreatic necrosis (proportion of patients differs 
by <10%)
Etiology (mean proportions differ by <10%)
Time (in days) between inclusion and onset of symptoms 
(mean differs by <10%)
Intervention
Allocation sequence
2 Computerized generated allocation, random number table
1 No more information
0 Quasi-randomization (date, etc.)
Concealment of allocation
2 Non-manipulable (call to data center, masked drug packages)
1 Potentially manipulable (sealed envelope, computer-
generated random number table) or randomization stated 




1 Blinding of physicians to allocation
0 Potentially unblinded, unblinded, or cannot tell
Description of antibiotic intervention
2 Indications for antibiotic crossover in control group described
1 Indications for antibiotic crossover stated afterwards
0 Indications for antibiotic crossover in control group not 
described
Description of method of feeding
2 Method of feeding in both groups described
1 Method of feeding only described in antibiotic or control 
group
0 Method of feeding not described
Participant flow
3 <10% loss to follow-up; reasons for loss to follow-up
outlined; intention-to-treat analysis
2 Two of above items
1 One of above items




for infection of pancreatic necrosis ranged from –0.077 
to 0.333 and the relative risk reduction (RRR) from –46.2 
to 87.8%. For mortality the ARR ranged from –0.02 to 0.2, 
the RRR from –10.5 to 80%. There was no overall signif-
icant reduction in infection of pancreatic necrosis, ARR 
0.055 (95% confidence interval (CI) –0.084 to 0.194) and
mortality, ARR 0.058 (95% CI –0.194 to 0.154;  table 4 ; 
 fig. 2 ,  3 ).
 Methodological Quality in Relation to Study Outcome 
 The Spearman correlation coefficient showed no 
significant relationship between the methodological qual-







flowpatient patient alloca- conceal- blinding description feeding selec- charac- tion ment of of antibiotic protocol
tion teristics sequence allocation intervention
Pederzoli et al. [14] 10 2 1 2 1 0 2 2 0
Sainio et al. [15] 8 2 1 2 1 0 2 0 0
Delcenserie et al. [13] 8 2 1 2 1 0 0 2 0
Schwarz et al. [16] 5 2 1 1 1 0 0 0 0
Spicak et al. [17] 2 2 0 0 0 0 0 0 0
Spicak et al. [18] 4 2 0 1 1 0 0 0 0
Isenmann et al. [7] 15 2 2 2 2 2 2 0 3
Dellinger et al. [19] 15 2 1 2 2 2 1 2 3
Table 3. Characteristics of the randomized controlled trials
Year n Setting Domain Intravenous 
antibiotic(s)
inclusion criteria etiology prognostic
score, mean
Ranson score
pancreatic necrosis on CT
Pederzoli
et al. [14]
1993 74 6 hospitals
Italy
PN on CECT Biliary 50%
Alcohol 32%
Other 18%
3.7 >30% PN in 53% of patients




1995 60 1 university
hospital
Finland
CRP >120 mg/l and
low contrast enhance-
ment on CECT or
extrapancreatic score
>4 on CT
Alcohol 100% 5.5 >33.3% PN in 80% of patients Cefuroxime
Delcenserie
et al. [13]
1996 23 1 hospital
France
Two or more fluid
collections on CT





1997 26 1 university
hospital
Germany
PN on CECT Biliary 42%
Alcohol 54%
Other 4%




2004 114 19 hospitals
Germany





2.3 >30% PN in 21% of patients Ciprofloxacin, 
metronidazole
Dellinger
et al. [19] 




PN >30% on CECT or
Balthazar grade E on CT
with either CRP >120 mg/l 




4.2 >30% PN in 57% of patients Meropenem
PN = Pancreatic necrosis; CECT = contrast-enhanced computed tomography; CRP = C-reactive protein; MOD = multiple organ dysfunction.
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ity of the trials and the reported risk of infected pancre-
atic necrosis ( table 5 ). With the Spearman correlation co-
efficient, an inverse significant relationship between 
methodological score and the ARR (correlation coeffi-
cient –0.841, p = 0.036) and RRR for mortality (correla-
tion coefficient–0.948, p = 0.004) was demonstrated ( ta-
ble 5 ;  fig. 4 ).
 Discussion 
 This study demonstrates that the study quality of 
the included RCTs was generally moderate. Interesting-
ly, the effect of antibiotic prophylaxis on mortality 
seemed smaller in studies of higher methodological 
quality.
 Strikingly, the findings in the study of van Nieuwen-
hoven et al.  [11] regarding the methodological quality of 
Table 4. Absolute (ARR) and relative risk reductions (RRR) of infected pancreatic necrosis and mortality
AB group Control group ARR 95% CI RRR 95% CI
Infected pancreatic necrosis
Pederzoli et al. [14] 5/41 10/33 0.181 –0.031; 0.393 0.576 (57.6%) –0.072; 0.832
Sainio et al. [15] 9/30a 12/30a 0.1 –0.175; 0.375 0.240 (24.0%) –0.502; 0.615
Delcenserie et al. [13] 0/11 4/12a 0.333 –0.064; 0.731 0.878 (87.8%) –1.008; 0.993
Schwarz et al. [16] 8/13 7/13 –0.077 –0.534; 0.380 –0.133 (–13.3%) –1.159; 0.405
Isenmann et al. [7] 7/58 5/56 –0.031 –0.162; 0.099 –0.317 (–31.7%) –2.721; 0.534
Dellinger et al. [19] 9/50 6/50 –0.060 –0.200; 0.080 –0.462 (–46.2%) –2.664; 0.417
Total 38/203 44/194 0.055 –0.084; 0.194 0.101 (10.1%) –0.430; 0.435
Mortality
Pederzoli et al. [14] 3/41 4/33 0.048 –0.113; 0.210 0.370 (37.0%) –1.361; 0.832
Sainio et al. [15] 1/30 7/30 0.2 –0.005; 0.405 0.800 (80.0%) –0.074; 0.963
Delcenserie et al. [13] 1/11 3/12 0.159 –0.238; 0.556 0.536 (53.6%) –1.657; 0.919
Schwarz et al. [16] 0/13 2/13 0.153 –0.128; 0.436 0.800 (80.0%) –2.801; 0.989
Isenmann et al. [7] 3/58 4/56 0.020 –0.086; 0.125 0.249 (24.9%) –1.895; 0.805
Dellinger et al. [19] 10/50 9/50 –0.020 –0.194; 0.154 –0.105 (–10.5%) –1.428; 0.497
Total 18/203 29/194 0.058 –0.017; 0.134 0.301 (30.1%) –0.403; 0.652
a Pancreatic abscess included.
    95% CI
    ARR, random
Pederzoli et al. [14]
Sainio et al. [15]
Delcenserie et al. [13]
Schwarz et al. [16]
Isenmann et al. [7]
Dellinger et al. [19]
Total
–1 0 1
Fig. 2. Meta-analysis: absolute risk reduction (ARR) of infected 
pancreatic necrosis.
     95% CI
     ARR, random
Pederzoli et al. [14]
Sainio et al. [15]
Delcenserie et al. [13]
Schwarz et al. [16]
Isenmann et al. [7]
Dellinger et al. [19]
Total
–1 0 1




the studies on SDD in intensive care patients were similar 
to ours, i.e. an inverse relationship between methodolog-
ical quality score and the benefit of antibiotic prophy-
laxis. An assessment of the methodological quality of 
studies based on the information in published articles 
could be influenced by flaws in reporting trials, i.e. some-
thing may not be reported although it was correctly per-
formed. Obviously, it is impossible to correct for this fac-
tor. In our meta-analysis, trials were weighted regardless 
of the methodological score. At this moment, there are no 
guidelines on how to weigh studies of specific method-
ological quality when combining results in a meta-analy-
sis.
 The heterogeneity of studies included in a meta-
analysis reduces the reliability in general  [22] . Several fac-
tors could have influenced the outcome of the present 
meta-analysis. Firstly, two studies  [13, 15] included only 
patients with alcohol-induced pancreatitis, whereas the 
other studies included patients regardless of the etiology 
of pancreatitis. There is controversy, however, about 
whether the etiology of pancreatitis influences mortality 
 [23–26] . Secondly, it is plausible that inclusion of less ill 
patients and patients without pancreatic necrosis leads to 
underestimation of the effect of systemic antibiotics in 
patients with acute pancreatitis. However, the patients in-
cluded in the study with the largest effect size of antibi-
otic prophylaxis on infection  [13] had the lowest mean 
Ranson score of 2.3, predicting mild pancreatitis. Third-
ly, only two studies were double-blind, placebo-con-
trolled  [7, 19] . In the other studies, the absence of blinding 
might have led to a higher prescription rate of antibiotics 
in the control group. The risk of early ‘cross-over’ (use of 
antibiotics in the control group) demands standardiza-
tion of antibiotic indications, especially in studies with-
out blinding. Total crossover rates were only reported in 
the studies by Sainio et al.  [15] (77%), Isenmann et al.  [7] 
(46%) and Dellinger et al.  [19] (52%). Finally, the antibiot-
ics used in the studies varied ( table 3 ); one study with imi-
penem  [14] , one study with meropenem  [19] , two with 
cephalosporins  [13, 15] , and two with a combination of 
third-generation fluoroquinolones and metronidazole  [7, 
16] . This makes it difficult to compare the outcome, since 
it could be influenced by, amongst others, the level of 
penetration of the antibiotics in (necrotic) pancreatic tis-
sue and the antimicrobial spectrum of the antibiotics 
 [27–30] .
 Since the use of broad-spectrum antibiotic prophylax-
is may lead to bacterial resistance  [31] , fungal infections 
 [32] , selective overgrowth of pathogens leading to, for in-
stance,  Clostridium difficile colitis  [33] and increased 
costs  [34] , the balance between beneficial and harmful 
effects of antibiotic prophylaxis should clearly be in favor 
of antibiotics in order to justify their use. The current 
meta-analysis demonstrated no beneficial effects of anti-
biotic prophylaxis on the incidence of both infected pan-
creatic necrosis and mortality. Furthermore, in the RCT 
from Isenmann et al.  [7] , patients receiving antibiotic 
prophylaxis experienced a significant increase in infec-
tions with bacteria resistant to the prophylactic antibiot-
ics administered.
Table 5. Association between methodological quality score and 
risk reduction of infection of pancreatic necrosis and mortality 
with linear regression analysis
Correlation coefficient p value
ARR infected necrosis –0.438 0.385
RRR infected necrosis –0.403 0.429
ARR mortality –0.841 0.036






































 Fig. 4. Significant relationship between 
methodological quality scores and risk re-
duction of mortality. ARR = Absolute risk 
reduction; RRR = relative risk reduction. 
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 Conclusion 
 Routine use of antibiotic prophylaxis in severe acute 
pancreatitis does not prevent infection of pancreatic ne-
crosis and mortality. The generally moderate quality of 
the studies may have contributed to an overly enthusi-
astic opinion on the effect of antibiotic prophylaxis in 
patients with severe acute pancreatitis. At present, opin-
ion-based medicine has taken over, resulting in wide-
spread use of antibiotic prophylaxis in severe acute pan-
creatitis. The inverse relationship between methodolog-
ical quality and the impact of antibiotic prophylaxis on 
mortality emphasizes the importance of high-quality 
RCTs.
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